<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Use of creatine kinase to detect myocardial injury</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Use of creatine kinase to detect myocardial injury</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Use of creatine kinase to detect myocardial injury</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan S Jaffe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Morrow, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myocardial injury is defined as the disruption of normal cardiac myocyte membrane integrity resulting in the loss into the extracellular space (including blood) of intracellular constituents including detectable levels of a variety of biologically active cytosolic and structural proteins such as troponin, creatine kinase, myoglobin, heart-type fatty acid binding protein, and lactate dehydrogenase. Injury is usually considered irreversible (cell death), but definitive proof that cell death is an inevitable consequence of the process is not available. Data indicate that very short periods of severe myocardial stress can lead to the release of cardiac troponin [<a href="#rid1">1-3</a>]. In experimental studies, release appears related to apoptotic cell death.</p><p>Causes of myocardial injury include trauma, toxins, viral infection, and catecholamines [<a href="#rid4">4</a>]. It used to be thought that ischemia or infarction consequent to an imbalance between the supply and demand of oxygen (and nutrients) was the most common cause, but clinically that is not the case. Myocardial injury without overt ischemia appears to be more common [<a href="#rid5">5</a>].</p><p>When a sufficient number of myocytes have died (myocyte necrosis) or lost function, acute clinical disease is apparent; examples include myocardial infarction (MI) or myocarditis. (See  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults"</a>.)</p><p>The biochemical characteristics and utility of creatine kinase for the diagnosis of and prognosis after acute MI will be reviewed here. Because of its pervasive availability and low cost, creatine kinase continues to be used as the primary biomarker for the diagnosis of acute MI in some regions of the world. Troponins, which are the preferred biomarkers for diagnosis and prognosis, are discussed separately. (See  <a class="medical medical_review" href="/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p><p class="headingAnchor" id="H516920712"><span class="h1">CREATINE KINASE AND CK-MB</span><span class="headingEndMark"> — </span>Creatine kinase (CK) and its MB isoenzyme (CK-MB) were the most commonly used serologic tests for the diagnosis of myocardial infarction prior to the widespread adoption of troponin. Their use has markedly diminished over time. Many institutions no longer offer CK-MB testing [<a href="#rid6">6</a>]. They are discussed here predominantly for those areas of the world where cardiac troponin assays are not widely available. (See  <a class="medical medical_review" href="/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p><p>It is difficult to find any situation in which CK-MB adds anything other than cost to the clinical utility of cardiac troponin (cTn) if that marker is used properly [<a href="#rid7">7</a>]. Thus, many recommend it no longer be used [<a href="#rid7">7,8</a>]. However, some experts continue to advocate for measurement of CK-MB in the setting of assessment of periprocedural (percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery [CABG]) myocardial infarction (MI) for epidemiological reasons. Also, some clinicians prefer the use of CK-MB for the detection of early reinfarction, although this is not guideline recommended. Nonetheless, there are data to support the usefulness of cTn for each of these applications. Some have even argued that using it at all will reduce the ability of clinicians to use cTn properly [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H516920732"><span class="h2">CK basics</span><span class="headingEndMark"> — </span>The enzyme CK (formerly referred to as creatine phosphokinase) exists as isoenzymes, which are dimers of M and B chains and exist in three combinations: MM, MB, and BB [<a href="#rid9">9</a>]. These isoenzymes reside in the cytosol and facilitate the egress of high-energy phosphates into and out of mitochondria. CK isoenzyme activity is distributed in many tissues, including skeletal muscle, but there is more of the CK-MB fraction in the heart [<a href="#rid10">10</a>]. Most muscles have more CK per gram than heart tissue [<a href="#rid11">11,12</a>]. Thus, skeletal muscle breakdown can lead to absolute increases in CK-MB in the plasma. In addition, in response to organ damage, including vigorous exercise [<a href="#rid13">13</a>], there is regeneration of skeletal muscle fibers and re-expression of proteins that existed during ontogeny, resulting in increased production of B chain CK protein [<a href="#rid12">12,14,15</a>]. A large percentage of the CK that is released is degraded locally or in lymph [<a href="#rid16">16</a>]. Reperfusion truncates this process and increases the rapidity and magnitude of egress of CK into plasma [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H516920862"><span class="h2">Total CK measurements for the detection of myocardial damage</span><span class="headingEndMark"> — </span>Elevations in total serum CK lack specificity for myocardial damage, which improves with measurement of the MB fraction. The normal range of CK also varies considerably; a twofold or greater increase in the CK concentration is required for diagnosis. This criterion can be problematic in older individuals who, because of their lower muscle mass, may have low baseline serum total CK and, during MI, may have elevated serum CK-MB with values of total CK that rise but remain within the normal range [<a href="#rid18">18-20</a>]. For these reasons, total CK has not been used in the diagnosis of myocardial damage for years.</p><p class="headingAnchor" id="H516920910"><span class="h2">CK-MB fraction for diagnosis of acute MI</span><span class="headingEndMark"> — </span>When cTn is available, CK-MB should not be used for the initial diagnosis of acute MI. If it is the only assay available, it can be used but is far less sensitive and specific.</p><p>Most assays measure CK-MB mass because they are more sensitive than activity assays. In addition, mass assays avoid, for the most part, detection of macrokinases (CK linked to IgG and dimers of mitochondrial CK) that can confound diagnosis with activity assays. The presence of macrokinases should be considered as one possibility when CK-MB is a very high percentage (&gt;20 percent) of total CK [<a href="#rid21">21</a>]. However, patients with chronic skeletal muscle disease often have falsely positive CK-MB results when percentage criteria are used [<a href="#rid15">15,22-24</a>]. The proportion of CK that is CK-MB can be as high as 50 percent with chronic skeletal muscle injury, such as dermatomyositis/polymyositis, due to increased production of B chain CK protein [<a href="#rid12">12,15,22</a>].</p><p class="headingAnchor" id="H516921034"><span class="h3">Specificity and sensitivity</span><span class="headingEndMark"> — </span>CK-MB was originally thought to have high specificity for cardiac tissue and was the preferred marker of myocardial injury for many years [<a href="#rid21">21</a>]. CK-MB typically begins to rise four to six hours after the onset of infarction but is not elevated in all patients until about 12 hours  (<a class="graphic graphic_figure graphicRef89580" href="/d/graphic/89580.html" rel="external">figure 1</a>) [<a href="#rid25">25,26</a>].</p><p>An elevated CK-MB is relatively specific for myocardial injury, particularly in patients with ischemic symptoms, when skeletal muscle damage is not present. Elevations return to baseline within 36 to 48 hours, in contrast to elevations in troponin, which can persist for as long as 10 to 14 days [<a href="#rid27">27</a>]. This means that CK-MB, unlike troponins, cannot be used for the late diagnosis of an acute MI but can be used to suggest infarct extension if levels rise again after declining. (See  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction"</a>.)</p><p>Sex-specific values are essential for diagnostic use [<a href="#rid28">28</a>].</p><p>Because CK-MB can be released from skeletal muscle, its diagnostic use is impaired when skeletal muscle injury is present [<a href="#rid29">29</a>]. Some have suggested using a ratio of CK-MB to total CK to improve specificity, but that approach markedly reduces the sensitivity.</p><p class="headingAnchor" id="H516921317"><span class="h2">Reinfarction and late diagnosis</span><span class="headingEndMark"> — </span>Since CK-MB levels return to baseline 36 to 48 hours after infarction, resampling can be used to detect very early reinfarction. Since cTn does not normalize that rapidly, it has been suggested that CK-MB might be of value in this area. It is now clear that cTn increases rapidly, albeit from an abnormal baseline in patients with reinfarction.</p><p class="headingAnchor" id="H543378319"><span class="h2">After myocardial revascularization</span><span class="headingEndMark"> — </span>CK-MB still has advocates for its use to define MI after myocardial revascularization with either PCI or CABG. As it detects larger infarcts, CK-MB holds more “weight” with some clinicians and trialists.</p><p class="headingAnchor" id="H516921337"><span class="h2">Why troponin is preferred</span><span class="headingEndMark"> — </span>Because of their increased sensitivity and specificity compared with CK-MB and other markers, troponins are preferred for the diagnosis of MI and for prognosis after MI. (See  <a class="medical medical_review" href="/d/html/86.html" rel="external">"Troponin testing: Clinical use", section on 'Diagnosis of acute MI'</a>.)</p><p class="headingAnchor" id="H2067906772"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend using cardiac troponins in preference to creatine kinase MB (CK-MB) for diagnostic and prognostic purposes. For most settings, it is unnecessary to obtain both values. (See  <a class="medical medical_review" href="/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Turer AT, Addo TA, Martin JL, et al. Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. J Am Coll Cardiol 2011; 57:2398.</a></li><li><a class="nounderline abstract_t">Weil BR, Young RF, Shen X, et al. Brief Myocardial Ischemia Produces Cardiac Troponin I Release and Focal Myocyte Apoptosis in the Absence of Pathological Infarction in Swine. JACC Basic Transl Sci 2017; 2:105.</a></li><li><a class="nounderline abstract_t">Weil BR, Suzuki G, Young RF, et al. Troponin Release and Reversible Left Ventricular Dysfunction After Transient Pressure Overload. J Am Coll Cardiol 2018; 71:2906.</a></li><li><a class="nounderline abstract_t">Moons KG, de Groot JA, Linnet K, et al. Quantifying the added value of a diagnostic test or marker. Clin Chem 2012; 58:1408.</a></li><li><a class="nounderline abstract_t">Melki D, Lugnegård J, Alfredsson J, et al. Implications of Introducing High-Sensitivity Cardiac Troponin T Into Clinical Practice: Data From the SWEDEHEART Registry. J Am Coll Cardiol 2015; 65:1655.</a></li><li><a class="nounderline abstract_t">Alvin MD, Jaffe AS, Ziegelstein RC, Trost JC. Eliminating Creatine Kinase-Myocardial Band Testing in Suspected Acute Coronary Syndrome: A Value-Based Quality Improvement. JAMA Intern Med 2017; 177:1508.</a></li><li><a class="nounderline abstract_t">Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation 2008; 118:2200.</a></li><li><a class="nounderline abstract_t">Jaffe AS, Lindahl B, Giannitsis E, et al. ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB. Eur Heart J 2021; 42:2260.</a></li><li><a class="nounderline abstract_t">Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem 1985; 54:831.</a></li><li><a class="nounderline abstract_t">Roberts R, Gowda KS, Ludbrook PA, Sobel BE. Specificity of elevated serum MB creatine phosphokinase activity in the diagnosis of acute myocardial infarction. Am J Cardiol 1975; 36:433.</a></li><li class="breakAll">Neumeier D. Tissue specific and subcellular distribution of creatine kinase isoenzymes. In: Creatine Kinase Isoenzymes, Lang H (Ed), Springer-Verlag, Berlin/Heidelberg 1981. p.85.</li><li><a class="nounderline abstract_t">Trask RV, Billadello JJ. Tissue-specific distribution and developmental regulation of M and B creatine kinase mRNAs. Biochim Biophys Acta 1990; 1049:182.</a></li><li><a class="nounderline abstract_t">Siegel AJ, Silverman LM, Evans WJ. Elevated skeletal muscle creatine kinase MB isoenzyme levels in marathon runners. JAMA 1983; 250:2835.</a></li><li><a class="nounderline abstract_t">Fontanet HL, Trask RV, Haas RC, et al. Regulation of expression of M, B, and mitochondrial creatine kinase mRNAs in the left ventricle after pressure overload in rats. Circ Res 1991; 68:1007.</a></li><li><a class="nounderline abstract_t">Wolf PL. Abnormalities in serum enzymes in skeletal muscle diseases. Am J Clin Pathol 1991; 95:293.</a></li><li><a class="nounderline abstract_t">Clark GL, Robison AK, Gnepp DR, et al. Effects of lymphatic transport of enzyme on plasma creatine kinase time-activity curves after myocardial infarction in dogs. Circ Res 1978; 43:162.</a></li><li><a class="nounderline abstract_t">Vatner SF, Baig H, Manders WT, Maroko PR. Effects of coronary artery reperfusion on myocardial infarct size calculated from creatine kinase. J Clin Invest 1978; 61:1048.</a></li><li><a class="nounderline abstract_t">Dillon MC, Calbreath DF, Dixon AM, et al. Diagnostic problem in acute myocardial infarction: CK-MB in the absence of abnormally elevated total creatine kinase levels. Arch Intern Med 1982; 142:33.</a></li><li><a class="nounderline abstract_t">Heller GV, Blaustein AS, Wei JY. Implications of increased myocardial isoenzyme level in the presence of normal serum creatine kinase activity. Am J Cardiol 1983; 51:24.</a></li><li><a class="nounderline abstract_t">Yusuf S, Collins R, Lin L, et al. Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction. Am J Cardiol 1987; 59:245.</a></li><li><a class="nounderline abstract_t">Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 1993; 88:750.</a></li><li><a class="nounderline abstract_t">Larca LJ, Coppola JT, Honig S. Creatine kinase MB isoenzyme in dermatomyositis: a noncardiac source. Ann Intern Med 1981; 94:341.</a></li><li><a class="nounderline abstract_t">Lenke LG, Bridwell KH, Jaffe AS. Increase in creatine kinase MB isoenzyme levels after spinal surgery. J Spinal Disord 1994; 7:70.</a></li><li><a class="nounderline abstract_t">Badsha H, Gunes B, Grossman J, Brahn E. Troponin I Assessment of Cardiac Involvement in Patients With Connective Tissue Disease and an Elevated Creatine Kinase MB Isoform Report of Four Cases and Review of the Literature. J Clin Rheumatol 1997; 3:131.</a></li><li><a class="nounderline abstract_t">Puleo PR, Guadagno PA, Roberts R, et al. Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB. Circulation 1990; 82:759.</a></li><li><a class="nounderline abstract_t">Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction. N Engl J Med 1994; 331:561.</a></li><li><a class="nounderline abstract_t">Jaffe AS, Landt Y, Parvin CA, et al. Comparative sensitivity of cardiac troponin I and lactate dehydrogenase isoenzymes for diagnosing acute myocardial infarction. Clin Chem 1996; 42:1770.</a></li><li><a class="nounderline abstract_t">Apple FS, Quist HE, Doyle PJ, et al. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003; 49:1331.</a></li><li><a class="nounderline abstract_t">Hollander JE, Levitt MA, Young GP, et al. Effect of recent cocaine use on the specificity of cardiac markers for diagnosis of acute myocardial infarction. Am Heart J 1998; 135:245.</a></li></ol></div><div id="topicVersionRevision">Topic 97 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658559" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28979949" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Brief Myocardial Ischemia Produces Cardiac Troponin I Release and Focal Myocyte Apoptosis in the Absence of Pathological Infarction in Swine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29929614" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Troponin Release and Reversible Left Ventricular Dysfunction After Transient Pressure Overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22952348" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Quantifying the added value of a diagnostic test or marker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25908071" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Implications of Introducing High-Sensitivity Cardiac Troponin T Into Clinical Practice: Data From the SWEDEHEART Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28806444" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Eliminating Creatine Kinase-Myocardial Band Testing in Suspected Acute Coronary Syndrome: A Value-Based Quality Improvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19015414" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Requiem for a heavyweight: the demise of creatine kinase-MB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33486520" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3896131" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The creatine-creatine phosphate energy shuttle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1190047" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Specificity of elevated serum MB creatine phosphokinase activity in the diagnosis of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1190047" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Specificity of elevated serum MB creatine phosphokinase activity in the diagnosis of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2364108" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tissue-specific distribution and developmental regulation of M and B creatine kinase mRNAs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6644963" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Elevated skeletal muscle creatine kinase MB isoenzyme levels in marathon runners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2009604" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Regulation of expression of M, B, and mitochondrial creatine kinase mRNAs in the left ventricle after pressure overload in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996538" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Abnormalities in serum enzymes in skeletal muscle diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27320" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effects of lymphatic transport of enzyme on plasma creatine kinase time-activity curves after myocardial infarction in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/659577" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of coronary artery reperfusion on myocardial infarct size calculated from creatine kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7053734" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnostic problem in acute myocardial infarction: CK-MB in the absence of abnormally elevated total creatine kinase levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6849263" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Implications of increased myocardial isoenzyme level in the presence of normal serum creatine kinase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3812273" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8339435" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7224380" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Creatine kinase MB isoenzyme in dermatomyositis: a noncardiac source.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8186592" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Increase in creatine kinase MB isoenzyme levels after spinal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19078168" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Troponin I Assessment of Cardiac Involvement in Patients With Connective Tissue Disease and an Elevated Creatine Kinase MB Isoform Report of Four Cases and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2203554" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702648" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8906075" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparative sensitivity of cardiac troponin I and lactate dehydrogenase isoenzymes for diagnosing acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881449" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9489972" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of recent cocaine use on the specificity of cardiac markers for diagnosis of acute myocardial infarction.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
